North America Anticoagulation Therapy Market – Industry Trends and Forecast to 2026

North America Anticoagulation Therapy Market – Industry Trends and Forecast to 2026

Short Description

By Treatment (Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Arterial Thromboembolism (AT), Stroke, Others), Therapeutic Class (Novel Oral Anticoagulants (NOAC), Heparin, Vitamin K Antagonists, Others), Drug Type (Bivalirudin, Dabigatran , Edoxaban, Betrixaban, Rivaroxaban , Apixaban, Enoxaparin, Dalteparin, Others), Route of Administration (Oral, Parenteral), Therapeutic Area (Cardiovascular, Respiratory, Oncology, Nephrology, CNS, Others), Procedure (Pre-Surgical Procedures, Post-Surgical Procedures, Kidney Dialysis, Heart Valve Replacement), Type (Generics, Branded), End User (Hospitals, Clinics, Homecare, Ambulatory Surgical Centres, Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), Country (U.S., Canada, Mexico).

Market Definition:
Anticoagulation therapy is a medication used in prevention of blood clots formation and to uphold blood vessels open. Anticoagulants are usually called as blood thinners but in reality it do not thin the blood but only helps to prevent or to reduce blood clot formation/thrombi. There are various anticoagulants available in the market such as vitamin K antagonists, heparin and novel oral anticoagulation which is used for prophylaxis/treatment of various thromboembolic disorders, such as heart attack (myocardial infarction), stroke and deep venous thrombosis (DVT).
The application of anticoagulation therapy includes prophylaxis/treatment of blood clots in DET/PE/AF, to reduce the chances of systemic embolism and stroke, treatment of thrombosis in heparin-induced thrombocytopenia (HIT) patients and HIT patients undergoing through percutaneous coronary intervention (PCI), prevention of venous thromboembolic events (VTE) in patients who have undergone elective total hip replacement (THR)/total knee replacement (TKR) surgery.

Market Segmentation:
North America anticoagulation therapy market is segmented into nine notable segments which are treatment, therapeutic class, drug type, route of administration, therapeutic area, procedure, type, end user and distribution channel.
• On the basis of treatment, the market is segmented into deep vein thrombosis (DVT), pulmonary embolism (PE), arterial thromboembolism (AT), stroke and others
• On the basis of therapeutic class, the market is segmented into novel oral anticoagulation (NOAC), heparin, vitamin k antagonists and others
• On the basis of drug type, the market is segmented into bivalirudin, dabigatran, edoxaban, betrixaban, rivaroxaban, apixaban, enoxaparin, delteparin and others
• On the basis of route of administration, the market is segmented into oral and injectable
• On the basis of therapeutic area, the market is segmented into cardiovascular diseases, oncology, respiratory, nephrology, CNS and others
• On the basis of procedure, the market is segmented into pre-surgical procedures, post-surgical procedures, kidney dialysis and heart valve replacement
• On the basis of type, the market is segmented into generics and branded
• On the basis of end user, the market is segmented into hospitals, clinics, homecare, ambulatory surgical centers and others
• On the basis of distribution channel, the market is segmented into hospital pharmacy, retail pharmacy and online pharmacy

Market Players
Some of the major players operating in this market are as follows:
• Hikma Pharmaceuticals PLC
• Mylan N.V.
• Teva Pharmaceutical Industries Ltd.
• Novartis AG
• Eisai Co., Ltd.
• Pfizer Inc.
• Sanofi
• F. Hoffmann-La Roche Ltd
• Fresenius Kabi AG
• Aspen Holdings
• Shanghai Fosun Pharmaceutical(Group)Co., Ltd.
• Cipla Inc
• Johnson & Johnson Services, Inc.
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Eagle Pharmaceuticals, Inc
• Endo Pharmaceuticals Inc
• Mitsubishi Tanabe Pharma Corporation
• Portola Pharmaceuticals, Inc.
• Taro Pharmaceutical Industries Ltd.

The single user license is non-downloadable and non-printable. Global Site license allows these actions.

1 Introduction
1.1 Objectives Of The Study
1.2 Market Definition
1.3 Overview Of North America Anticoagulation Therapy Market
1.4 Limitations
1.5 Markets Covered
2 Market Segmentation
2.1 Markets Covered
2.2 North America Anticoagulation Therapy Market: Geographical Scope
2.3 Years Considered For The Study
2.4 Currency And Pricing
2.5 Dbmr Tripod Data Validation Model
2.6 Primary Interviews With Key Opinion Leaders
2.7 Dbmr Market Position Grid
2.8 Dbmr Vendor Share Analysis
2.9 Multivariate Modeling
2.10 Products Lifeline Curve
2.11 Secondary Sources
2.12 Assumptions
3 Market Overview
3.1 Drivers
3.1.1 Rising Prevalence Of Venous Thromboembolism And Pulmonary Embolism
3.1.2 Increasing Usage Of Noacs As Alternatives To Warfarin
3.1.3 Growing Number Of Surgeries
3.1.4 Number Of Patients Requiring Lifelong Anticoagulation Therapy
3.2 Restraints
3.2.1 Increasing Government Restriction
3.2.2 Product Recalls
3.2.3 High Cost Of Drug Development
3.3 Opportunities
3.3.1 Strategic Initiatives By The Market Players
3.3.2 Increasing Developments In Bioengineering:
3.4 Challenges
3.4.1 Patent Expiry
3.4.2 Side-effects Of Heparin
4 Executive Summary
5 Premium Insights
6 North America Anticoagulation Therapy Market, By Pipeline Analysis
6.1 Overview
7 North America Anticoagulation Therapy Market, By Treatment
7.1 Overview
7.2 Deep Vein Thrombosis (Dvt)
7.3 Pulmonary Embolism (Pe)
7.4 Arterial Thromboembolism (At)
7.5 Stroke
7.6 Others
8 North America Anticoagulation Therapy Market, By Therapeutic Class
8.1 Overview
8.2 Novel Oral Anticoagulants (Noac)
8.2.1 Factor Xa Inhibitors
8.2.2 Direct Thrombin Inhibitors
8.2.3 Antithrombin Protein Therapeutics
8.3 Heparin
8.3.1 Unfractionated Heparin
8.3.2 Low Molecular Weight Heparins (Lmwh)
8.3.3 Ultra Low Molecular Weight Heparins (Ulmwh)
8.4 Vitamin K Antagonists
8.4.1 Warfarin
8.4.2 Coumarins
8.5 Others
9 North America Anticoagulation Therapy Market, By Drug Type
9.1 Overview
9.2 Bivalirudin
9.3 Dabigatran
9.4 Edoxaban
9.5 Betrixaban
9.6 Rivaroxaban
9.7 Apixaban
9.8 Enoxaparin
9.9 Dalteparin
9.10 Others
10 North America Anticoagulation Therapy Market, By Route Of Administration
10.1 Overview
10.2 Oral
10.3 Injectable
10.3.1 Subcuteneous
10.3.2 Intravenous
10.3.3 Intraperitoneal
10.3.4 Others
11 North America Anticoagulation Therapy Market, By Therapeutic Area
11.1 Overview
11.2 Cardiovascular Diseases
11.2.1 Coronary Artery Diseases
11.2.2 Myocardial Infarction
11.2.3 Cardiac Arrhythmia
11.3 Oncology
11.4 Respiratory
11.5 Nephrology
11.6 Cns
11.7 Others
12 North America Anticoagulation Therapy Market, By Procedure
12.1 Overview
12.2 Pre-surgical Procedures
12.3 Post Surgical Procedures
12.4 Kidney Dialysis
12.5 Heart Valve Replacement
13 North America Anticoagulation Therapy Market, By Type
13.1 Overview
13.2 Generics
13.3 Branded
13.3.1 Eliquis
13.3.2 Xarelto
13.3.3 Pradaxa
13.3.4 Lovenox
13.3.5 Others
14 North America Anticoagulation Therapy Market, By End User
14.1 Overview
14.2 Hospitals
14.3 Clinics
14.4 Homecare
14.5 Ambulatory Surgical Centers
14.6 Others
15 North America Anticoagulation Therapy Market, By Distribution Channel
15.1 Overview
15.2 Hospital Pharmacy
15.3 Retail Pharmacy
15.4 Online Pharmacies
16 North America Anticoagulation Therapy Market, By Geography
16.1 North America
16.1.1 U.S.
16.1.2 Canada
16.1.3 Mexico
17 North America Anticoagulation Therpay Market, Company Landscape
17.1 Company Share Analysis: North America
18 Swot Analysis
18.1 Strength
18.1.1 Significant Increase In Shares In The Market-focused Segment
18.1.2 Established Presence In Market
18.2 Weakness
18.2.1 Dependency On Third-party Supplier
18.3 Opportunity
18.3.1 Strategic Investments /Acquisition/ Partnerships / Product Launch/ Approvals
18.4 Threat
18.4.1 Complexity And Stringent Requirements For The Drug Approval
18.5 Data Bridge Market Research Analysis
19 Company Profiles
19.1 Bristol-myers Squibb Company
19.1.1 Company Snapshot
19.1.2 Revenue Analysis
19.1.3 Company Share Analysis
19.1.4 Geographical Presence
19.1.5 Product Portfolio
19.1.6 Recent Development
19.2 Pfizer Inc.
19.2.1 Company Snapshot
19.2.2 Revenue Analysis
19.2.3 Company Share Analysis
19.2.4 Geographical Presence
19.2.5 Product Portfolio
19.2.6 Recent Developments
19.3 Bayer Ag
19.3.1 Company Snapshot
19.3.2 Revenue Analysis
19.3.3 Company Share Analysis
19.3.4 Geographical Presence
19.3.5 Product Portfolio
19.3.6 Recent Developments
19.4 Johnson & Johnson Services, Inc.
19.4.1 Company Snapshot
19.4.2 Revenue Analysis
19.4.3 Company Share Analysis
19.4.4 Geographical Presence
19.4.5 Product Portfolio
19.4.6 Recent Developments
19.5 Sanofi
19.5.1 Company Snapshot
19.5.2 Revenue Analysis
19.5.3 Company Share Analysis
19.5.4 Geographical Presence
19.5.5 Product Portfolio
19.5.6 Recent Development
19.6 Boehringer Ingelheim International Gmbh
19.6.1 Company Snapshot
19.6.2 Revenue Analysis
19.6.3 Geographical Presence
19.6.4 Product Portfolio
19.6.5 Recent Development
19.7 Aspen Holdings
19.7.1 Company Snapshot
19.7.2 Revenue Analysis
19.7.3 Geographical Presence
19.7.4 Product Portfolio
19.7.5 Recent Developments
19.8 Cipla Inc.
19.8.1 Company Snapshot
19.8.2 Revenue Analysis
19.8.3 Geographical Presence
19.8.4 Product Portfolio
19.8.5 Recent Development
19.9 Daiichi Sankyo Company, Limited
19.9.1 Company Snapshot
19.9.2 Revenue Analysis
19.9.3 Geographical Presence
19.9.4 Product Portfolio
19.9.5 Recent Developments
19.10 Eagle Pharmaceuticals, Inc.
19.10.1 Company Snapshot
19.10.2 Revenue Analysis
19.10.3 Product Portfolio
19.10.4 Recent Development
19.11 Eisai Co., Ltd.
19.11.1 Company Snapshot
19.11.2 Revenue Analysis
19.11.3 Geographical Presence
19.11.4 Product Portfolio
19.11.5 Recent Development
19.12 Endo Pharmaceuticals Inc.
19.12.1 Company Snapshot
19.12.2 Revenue Analysis
19.12.3 Geographical Presence
19.12.4 Product Portfolio
19.12.5 Recent Development
19.13 F. Hoffmann-la Roche Ltd
19.13.1 Company Snapshot
19.13.2 Revenue Analysis
19.13.3 Geographical Presence
19.13.4 Product Portfolio
19.13.5 Recent Development
19.14 Fresenius Kabi Ag
19.14.1 Company Snapshot
19.14.2 Revenue Analysis
19.14.3 Geographical Presence
19.14.4 Product Portfolio
19.14.5 Recent Developments
19.15 Hikma Pharmaceuticals Plc
19.15.1 Company Snapshot
19.15.2 Revenue Analysis
19.15.3 Geographical Presence
19.15.4 Product Portfolio
19.15.5 Recent Development
19.16 Mitsubishi Tanabe Pharma Corporation.
19.16.1 Company Snapshot
19.16.2 Revenue Analysis
19.16.3 Geographical Presence
19.16.4 Product Portfolio
19.16.5 Recent Development
19.17 Mylan N.V.
19.17.1 Company Snapshot
19.17.2 Revenue Analysis
19.17.3 Geographical Presence
19.17.4 Product Portfolio
19.17.5 Recent Developments
19.18 Novartis Ag
19.18.1 Company Snapshot
19.18.2 Revenue Analysis
19.18.3 Geographical Presence
19.18.4 Product Portfolio
19.18.5 Recent Development
19.19 Portola Pharmaceuticals, Inc.
19.19.1 Company Snapshot
19.19.2 Revenue Analysis
19.19.3 Product Portfolio
19.19.4 Recent Development
19.20 Shanghai Fosun Pharmaceutical (Group)co. Ltd.
19.20.1 Company Snapshot
19.20.2 Revenue Analysis
19.20.3 Geographical Presence
19.20.4 Product Portfolio
19.20.5 Recent Development
19.21 Taro Pharmaceutical Industries Ltd.
19.21.1 Company Snapshot
19.21.2 Revenue Analysis
19.21.3 Geographical Presence
19.21.4 Product Portfolio
19.21.5 Recent Development
19.22 Teva Pharmaceutical Industries Ltd.
19.22.1 Company Snapshot
19.22.2 Revenue Analysis
19.22.3 Geographical Presence
19.22.4 Product Portfolio
19.22.5 Recent Developments
20 References
21 Questionnaire
22 Related Reports

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook